Immutep Initiates Phase III Trial for Lung Cancer

Immutep Ltd (AU:IMM) has released an update.

Immutep Limited has launched the TACTI-004 Phase III trial, a significant step towards establishing a new standard of care for metastatic non-small cell lung cancer. The trial will assess the efficacy of their LAG-3 immunotherapy, eftilagimod alfa, in combination with KEYTRUDA and chemotherapy. With approvals from Australia and anticipated global clearances, Immutep aims to enroll its first patient in early 2025, marking a pivotal moment for the company in the biotech sector.

For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.